Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
Hedge Fund 13F Stock Picks: Profiting From Idea Season

Hedge Fund 13F Stock Picks: Profiting From Idea Season

Hedge fund manager third quarter stock picks are revealed, and sorting through the 13F filings provides value investing ideas.

Making the Most of Idea Season

The 13HF filings currently pouring into the SEC offer good clues about stocks that are worth further investigation.

Seth Klarman's Baupost Buys HP, BP After Shares Collapse

Seth Klarman's Baupost Buys HP, BP After Shares Collapse

The hedge fund firm makes the computer and oil companies its biggest bets.

Inhibitex Soars as Investors See Another Pharmasset in the Making

Inhibitex Soars as Investors See Another Pharmasset in the Making

Inhibitex's Hep C drug candidate looks as potent as the competing Pharmasset drug which has garnered so much investor attention.

Biotech Stock Mailbag: Idenix vs. Pharmasset?

Biotech Stock Mailbag: Idenix vs. Pharmasset?

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's purchase of Anadys provides the third drug in what may be the first all-oral hepatits C regimen to start late-stage trials.

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Roche buys Anadys for $230 million as large drug makers seek new drugs for combination therapy against hepatitis C.

Idenix Pharmaceuticals Inc. (IDIX): Today's Featured Health Care Loser

Idenix Pharmaceuticals Inc. (IDIX): Today's Featured Health Care Loser

Idenix Pharmaceuticals Inc was a leading decliner within the health care sector, falling 20 cents (-3.9%) to $5 on average volume.

10 Hep C Stocks on Wall Street's Watch List

10 Hep C Stocks on Wall Street's Watch List

An upcoming hepatitis C research meeting has investors paying close attention to Hep C drug developers.

Achillion CEO Needs to Deliver on Deal Talk

Achillion CEO Needs to Deliver on Deal Talk

Achillion seeking Big Pharma partners for its stable of hepatitis C drugs.

Biotech Stock Mailbag: Idenix Pharma

Biotech Stock Mailbag: Idenix Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

11 Biotech Stocks Loved or Hated by Hedge Funds

11 Biotech Stocks Loved or Hated by Hedge Funds

A list of biotech stocks that saw signficant buying and selling from hedge funds in the second quarter.

Seth Klarman's Baupost Buys Microsoft, BP

Seth Klarman's Baupost Buys Microsoft, BP

Seth Klarman's Baupost Group initiated new positions in the tech firm and oil company last quarter.

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Pharmaceuticals (Nasdaq:IDIX) is trading at unusually high volume Tuesday with 2.1 million shares changing hands. It is currently at 4.1 times its average daily volume and trading down $1.06 (-20.3%).

Vertex: Four Hep C Drugs Better Than Three

Vertex: Four Hep C Drugs Better Than Three

Vertex announces results from a Quad therapy which may cut Hep C treatment time in half.

Idenix Stock Gaps Down On Today's Open (IDIX)

Idenix Stock Gaps Down On Today's Open (IDIX)

Shares of Idenix Pharmaceuticals (Nasdaq:IDIX) were gapping down Friday morning with an open price 10.5% lower than Thursday's closing price. The stock closed at $3.24 yesterday and opened today's trading at $2.90.

Expedia: After-Hours Trading

Expedia: After-Hours Trading

Expedia, Tempur-Pedic, Seagate and Hercules Offshore were among the stocks seeing trading interest in Thursday's after-hours session.

Idenix Stock Gaps Down On Today's Open (IDIX)

Idenix Stock Gaps Down On Today's Open (IDIX)

Shares of Idenix Pharmaceuticals (Nasdaq:IDIX) were gapping down Thursday morning with an open price 26.2% lower than Wednesday's closing price. The stock closed at $4.01 yesterday and opened today's trading at $2.96.

Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences

Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will present a corporate overview at the 13 th Annual BIO CEO & Investor Conference on February 14, 2011 at 10:30 a.

Biotech Calendar: Key Dates for February

Biotech Calendar: Key Dates for February

Here's a list of December's potentially stock-moving biotech events.

Hep C Update: Vertex, Merck and Gilead

Hep C drug updates from this weekend's closely watched liver disease meeting.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct. 8, 2010.

Biotech Stock Mailbag: Hep C Stocks to Watch

Biotech Stock Mailbag: Hep C Stocks to Watch

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

China Sky One, Idenix: Volume Movers

China Sky One, Idenix: Volume Movers

Several stocks trading below $10, including China Sky One Medical, were poised to move on above-average volume Tuesday.

Idenix: Two Hep C Drugs on Clinical Hold

Idenix asked by FDA to temporarily halt clinical work on two Hep C drugs due to worries about liver toxicity.

The Essential Biotech Sector Fall Preview

The Essential Biotech Sector Fall Preview

A biotech back-to-school guide with everything investors need to prepare for a busy fall season.

Seven Little-Known Bull Markets

Seven Little-Known Bull Markets

Plenty of stocks are offering nice setups -- you just have to look for them.

Vantage Drilling, Zoran: Volume Movers

Vantage Drilling, Zoran: Volume Movers

Several stocks trading near $5, including Vantage Drilling, were poised to move on above-average volume Tuesday.

Idenix Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Idenix Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Idenix Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Stock Offerings: Pacific Capital

Stock Offerings: Pacific Capital

Pacific Capital's share price was cut in half Thursday after the bank announced plans to sell shares at a steep discount